drugset / Trial / NCT00280956
Open Label Natalizumab Safety Extension Study for Subjects With Crohn's Disease
Non-randomizedSingle-groupOpen-label
Summary
The primary objective of this study is to evaluate the long-term tolerability and safety of natalizumab when administered a dose of 300 mg intravenously (IV) to subjects with Crohn's Disease who have previously participated in studies CD251, CD301, CD303, CD306, or CD307.
Timeline
- Start
- 2002-07
- Primary completion
- 2004-09
- Completion
- 2004-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | natalizumab | Monoclonal antibody | 300 mg | Intravenous |